newsfilter
← Latest News
GlobeNewswire·

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratutrelvir, a